- Track your favorite companies
- Receive email alerts for new filings
- Personalized dashboard of news and more
- Access all data and search results
Content analysis
?Positive | ||
Negative | ||
Uncertain | ||
Constraining | ||
Legalese | ||
Litigous | ||
Readability |
H.S. sophomore Good
|
- 10-Q Quarterly report
- 10.2 Form of Notice of Grant of Stock and Stock Option Agreement
- 10.3 Form of Notice of Grant and Stock Option Agreement
- 31.1 Certification Principal Executive Officer Pursuant to Rule 13A-14(A)
- 31.2 Certification Principal Financial Officer Pursuant to Rule 13A-14(A)
- 32.1 Certification of CEO and CFO As Required by Rule 13A-14(B)
EXHIBIT 32.1
CERTIFICATION
Mark McDade, Chief Executive Officer, and Andrew L. Guggenhime, Senior Vice President and Chief Financial Officer, of PDL BioPharma, Inc. (the “Registrant”), each hereby certifies in accordance with 18 U.S.C. 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, that, based on his knowledge:
(1) the Quarterly Report on Form 10-Q for the quarter ended June 30, 2007 of the Registrant, to which this certification is attached as an exhibit (the “Report”), fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934 (15 U.S.C. 78m); and
(2) the information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Registrant.
A signed original of this written statement required by Section 906 will be provided to the Securities and Exchange Commission or its staff upon request.
Dated: August 9, 2007
/s/ Mark McDade |
Mark McDade |
Chief Executive Officer (Principal Executive Officer) |
/s/ Andrew L. Guggenhime |
Andrew L. Guggenhime |
Senior Vice President and Chief Financial Officer (Principal Financial Officer) |